A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body

Study summary

The main purpose of this study is to see how safe the investigational drug known as LY3009120 is and whether it will work to help people with advanced cancer or cancer that has spread to other parts of the body.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedLY3009120 capsule

The study team can explain what participation involves.

Who it may be forNeoplasms · Neoplasm Metastasis

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 27, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?6 U.S. locations

Locations may change over time.

Who runs it?Eli Lilly and Company

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: Eli Lilly and Company
Interventions being studied: Drug: LY3009120 capsule

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Advanced or metastatic cancer
Other available therapies have failed to cure the cancer
The cancer that has no proven effective therapy
The cancer can be biopsied (depending on the tumor type and/or the dose of drug received, tumor biopsies may be required)
Able to swallow capsules

Reasons someone may not be able to joinExclusion criteria

Have active cancer in the brain or spinal cord
Have an active infection of any kind (fungal, viral, or bacterial)
Have a cancer of the blood
Are pregnant or breastfeeding
Have some types of eye problems or impairments

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Pinnacle Oncology HematologyScottsdale, Arizona
Massachusetts General HospitalBoston, Massachusetts
University of Texas MD Anderson Cancer CenterHouston, Texas
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.Nedlands
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.Villejuif
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.Barcelona

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 27, 2019. Always confirm current availability with the study team.

View original record ↗